WA-PARSE-BIOSCIENCES
16.5.2023 14:01:35 CEST | Business Wire | Press release
Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced an agreement with Israel-based Ornat Biochemicals and Laboratory Equipment to extend Parse’s reach in the Middle East.
“The past year has represented a considerable leap forward for Parse, with demand growing significantly for our Evercode single cell sequencing solutions,” noted Parse CEO and co-founder Alex Rosenberg, Ph.D. “Partnering with a premier distributor in the Middle East positions us well in the region for continued growth.”
Parse’s agreement with Ornat will give researchers in Israel access to its full single cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Capture, and the Parse Biosciences data analysis solution. The agreement bolsters Parse’s plan to offer its products in key international markets.
“Parse is accelerating the pace of single cell research with its Evercode technology. We're elated to partner with them to introduce this state of the art technology to the thriving biotech community in Israel,” said Ornat CEO, Eyal Lev.
About Parse Biosciences
Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.
With technology developed at The University of Washington by co-founders Alex Rosenberg and Charles Roco, Parse has raised over $50 million in capital and is now used by nearly 1,000 customers across the world. Its growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, Gene Capture, and a data analysis solution.
Parse Biosciences is based in Seattle’s vibrant South Lake Union district, where it recently opened a 34,000 square foot headquarters and state-of-the-art laboratory. To learn more, please visit https://www.parsebiosciences.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pinion Insurance Appoints Gary S. Maier as US CEO29.9.2026 14:31:00 CEST | Press release
Veteran insurance executive to lead US growth as specialty carrier expands its MGA platform and technology offerings Pinion Insurance, the London-headquartered specialty insurance carrier established earlier this year, today announced the appointment of Gary S. Maier as US Chief Executive Officer, effective today. Maier brings nearly four decades of insurance industry experience across underwriting, distribution, MGAs, product development, and corporate development. He will lead Pinion’s US operations and drive the expansion of its specialty insurance platform, which provides capacity to MGAs across the US, UK and European markets. “Gary’s experience is a strong fit with Pinion’s focus on underwriting excellence, innovation, and close collaboration with MGAs,” said Laura Baird, Pinion Co-Founder and Group Chief Technology Officer. “He is a highly respected industry leader and innovator, and we are delighted to welcome him to the team.” Maier joins Pinion from Ledger Risk Markets, where
New AI Research from GFT Technologies: 84% of CIOs Have Canceled an AI Project Over Legacy System Limits29.9.2026 14:07:00 CEST | Press release
Global survey of 945 CIOs and CTOs at $500M+ companies finds outdated infrastructure, AI bubble fears, geopolitical and regulatory uncertainty, and workforce distrust are slowing meaningful AI progress A new AI study from GFT Technologies, an AI-centric global digital transformation company, finds that legacy infrastructure is one of the biggest obstacles to enterprise AI success, with the vast majority of technology leaders reporting it has forced them to abandon AI initiatives. The GFT survey, conducted by Wakefield Research among 945 CIOs and CTOs across 19 countries at companies with at least $500M in annual revenue (fielded August 11-31, 2026), reveals that AI's promise and its risks are accelerating in tandem. Key themes include legacy infrastructure undermining AI initiatives, skepticism over AI's return on investment, geopolitical and regulatory uncertainty reshaping strategy, distrust of how companies explain workforce decisions, and rising personal risk for technology leaders
Heaviside Industries Awarded $99M IDIQ Contract to Provide MOTH Spectrum Analyzers to U.S. Army29.9.2026 14:00:00 CEST | Press release
MOTH’s low size, weight, power, and cost enable distributed spectrum awareness in support of U.S. Army EMSO priorities Heaviside Industries, a builder of multi-domain precision munitions platforms, announced it has been awarded a $99 million firm-fixed-price, indefinite delivery, indefinite quantity (IDIQ) contract by the U.S. Army to deliver its MOTH radio frequency (RF) spectrum analyzers in support of the Army’s electromagnetic spectrum operations (EMSO) priorities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929455358/en/ The five-year contract was awarded by U.S. Army Contracting Command at Aberdeen Proving Ground, Maryland and includes system procurement, fielding, upgrades, and sustainment. As unmanned systems proliferate and adversaries increasingly exploit the electromagnetic spectrum, the Army requires EMSO capabilities that are scalable, adaptable, and rapidly fieldable to maintain an advantage in the spectr
Royal Yacht International Represents Buyer in Landmark 132M Lürssen as Founder Predicts: “The Billion-dollar Yacht Is Coming”29.9.2026 14:00:00 CEST | Press release
The Monaco-Miami advisory firm is building a different model for ultra-high-value yacht acquisitions, combining access, negotiation, technical expertise and selective, founder-led representation. Royal Yacht International has announced PROJECT M, a fully custom 132-metre Lürssensuperyacht exceeding 6,000 GT. But for Royal Yacht International Founder and CEO Tommaso Chiabra, the project is less about size than what it represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260928365204/en/ Project M At the very top of the luxury market, the world’s most exceptional yachts are becoming increasingly difficult to reproduce. Only a small number of shipyards can execute projects of this scale. Construction takes years. Specialist capacity is finite. Build slots are scarce. And replacement cost can change dramatically between contract signing and delivery. “People look at purchase price. Sophisticated owners look at replacement
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America29.9.2026 14:00:00 CEST | Press release
This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region. Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. Under the terms of the agreement, Knight will be responsible for seeking the necessary regulatory approvals and commercialising mogamulizumab for mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of CTCL, a rare non-Hodgkin’s lymphoma, in Argentina, Brazil, Colombia and Mexico. Knight will hold exclusive distributi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom